Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

Background: Clear cell renal cell carcinoma (ccRCC) is a highly aggressive renal cancer subtype and lacks highly precise individualized treatment options. Thus, we used a novel computational framework ...

Papillary renal cell carcinoma is a type of kidney cancer that starts in the kidneys' tubules. Read about the symptoms, diagnosis, treatment, and outlook.

512Background: Non-clear cell renal cell carcinoma (nccRCC) includes several molecularly distinct subtypes of renal carcinoma. Due to their rarity, nccRCC subtypes have been understudied, and ...

Choueiri TK, Lee JL, Merchan JR, et al. Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): safety, efficacy and subgroup analysis ...